JGC
MLTX icon

J. Goldman & Co’s MoonLake Immunotherapeutics MLTX Stock Holding History

J. Goldman & Co’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.55M Buy
136,900
+35,433
+35% +$587K 0.07% 285
2025
Q4 		$1.34M Buy
+101,467
New +$1.2M 0.04% 356
2025
Q2 		– Sell
-14,664
Closed -$597K – 569
2025
Q1 		$573K Buy
+14,664
New +$632K 0.01% 399
2024
Q4 		– Sell
-16,162
Closed -$815K – 567
2024
Q3 		$815K Sell
16,162
-2,005
-11% -$94K 0.02% 310
2024
Q2 		$799K Buy
18,167
+1,060
+6% +$44.9K 0.02% 323
2024
Q1 		$859K Buy
+17,107
New +$928K 0.03% 282

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

J. Goldman & Co's MLTX Position: Q1 2026 in Review

J. Goldman & Co increased its MoonLake Immunotherapeutics (MLTX) stake by 35% in Q1 2026, buying an estimated $587K and bringing the position to 136,900 shares worth $2.55M. The position accounts for 0.07% of the portfolio, ranked #285.

J. Goldman & Co first reported a position in MLTX in Q1 2024 and has held it in 6 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • J. Goldman & Co held 136,900 shares of MoonLake Immunotherapeutics worth $2.55M as of Q1 2026.
  • J. Goldman & Co bought 35,433 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $587K.
  • MoonLake Immunotherapeutics made up 0.07% of J. Goldman & Co's portfolio in Q1 2026, its #285 holding.
  • J. Goldman & Co first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 6 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.